Design of effective immunotherapy for human autoimmunity

Marc Feldmann () and Lawrence Steinman ()
Additional contact information
Marc Feldmann: Kennedy Institute of Rheumatology, Faculty of Medicine, Imperial College School of Medicine, ARC Building
Lawrence Steinman: Stanford University

Nature, 2005, vol. 435, issue 7042, 612-619

Abstract: Abstract A better understanding of the molecules involved in immune responses has identified many potential targets for the treatment of autoimmune diseases. But although successful therapies have been found for immune disorders in animal studies, few have passed the much harder test of treating human diseases. So far, non-antigen-specific approaches, such as the blocking of tumour-necrosis factor, are achieving some success but the same is not true for antigen-specific approaches. Future therapies will probably include both non-antigen-specific strategies that target cytokines (cell–cell signalling molecules) or block the molecules that stimulate immune responses, and antigen-specific therapies that induce tolerance to self antigens.

Date: 2005
References: Add references at CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
https://www.nature.com/articles/nature03727 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:435:y:2005:i:7042:d:10.1038_nature03727

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/nature03727

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().